How Robots Are Introducing A New Dimension To Healthcare Service Delivery

Pharmaceutical

Botanical Bounty: Cracking the Herbal Medicine ...

Herbal Medicine, rooted in ancient traditions across cultures worldwide, has witnessed a remarkable evolution in the modern era. The global Herbal Medicine Market has experienced significant growth...

Mar 27, 2024

pharma-news-for-regeneron-novartis-novo-nordisk-abbvie
Regeneron’s Odronextamab BLA; Novo Nordisk’s Cardior Pharmaceuticals Acquisition; Novartis’ Fabhalta CHMP Approval; Idorsia’s TRYVIO FDA Approval; AbbVie’s Landos Biopharma Acquisition

Regeneron Updates Progress on Biologics License Application for Odronextamab Regeneron Pharmaceuticals, Inc. has announced that the FDA has issued Complete Response Letters (CRLs) regarding the Biologics License Application (BLA) for odronextamab in cases of relapsed/refractory (R/R) follicular lymphoma (FL) and...

Find More
gene-therapies-for-epidermolysis-bullosa-treatment
Gene Therapies for Epidermolysis Bullosa Treatment: The Next Frontier in Dermatology

Epidermolysis bullosa is a genetic skin condition marked by severe skin sensitivity and the formation of blisters even from minor friction or injury. This disorder arises from genetic changes that impact the proteins crucial for upholding the skin’s structural strength. The degree of severity in epidermolysis bullo...

Find More
rezdiffra-for-nash-treatment
Madrigal’s Rezdiffra Breakthrough Transforms NASH Treatment, Leading the Way for Next-Gen Therapies

The prolonged wait for an effective remedy for non-alcoholic steatohepatitis (NASH) has concluded with the FDA’s approval of the inaugural drug for this fatty liver condition. Madrigal Pharmaceuticals’ resmetirom, soon available as Rezdiffra, has achieved the milestone of becoming the primary therapy for NASH to re...

Find More

More Views & Analysis

digestive-health-products-key-factors-and-market-dynamics
Digestive Health Products: Exploring the Market Dynamics and Key Factors Driving the Demand

Over the years, the landscape of Digestive Health Products has undergone significant evolution driven by advancements in scientific understanding, changing consumer preferences, and emerging market trends. As per the latest study by DelveInsight, the global Digestive Health Products market was valued at USD 39,345....

Find More

pharma-news-for-bms-orchard-madrigal-astrazeneca
Bristol Myers Squibb’ Karuna Therapeutics Buyout; Orchard Therapeutics’ Lenmeldy FDA Approval; Madrigal Pharmaceuticals’ Rezdiffra FDA Approval; AstraZeneca’s Acquisition of Amolyt Pharma; Prilenia’s Pridopidine EU Marketing Approval

Bristol Myers Squibb Enhances Neuroscience Arm with Karuna Therapeutics Buyout Bristol Myers Squibb has declared the finalization of its purchase of Karuna Therapeutics, Inc. With this acquisition concluded Karuna’s shares are no longer being traded on the Nasdaq Global Select Market, as Karuna is now fully owne...

Find More

emerging-therapies-for-nephrotic-syndrome-treatment
Promising Nephrotic Syndrome Treatments: A Look into the Future

Nephrotic syndrome is a clinical condition characterized by significant protein in the urine (exceeding 40 mg/m2/h), leading to low levels of albumin (below 30 g/L), which in turn causes high levels of lipids, swelling, and a range of associated complications. The epidemiological assessment of nephrotic syndrome...

Find More

trop2-inhibitors-for-cancer-treatment
Unveiling the Potential of TROP-2 Inhibitors: A New Frontier in Cancer Treatment

Trophoblast cell surface antigen-2 (TROP-2) is a 35-kDa protein found on cell membranes, made of sugars and a protein chain, serving as a transmitter of calcium signals. It is produced by the TACSTD2 gene and shares a structural similarity with the epithelial cell adhesion molecule (EpCAM). TROP2, although ident...

Find More

Pharma News for BeiGene, GSK, Sandoz, Travere
BeiGene’s BRUKINSA Gets FDA Accelerated Approval; GSK’s Positive Results in DREAMM-8 Phase III; Sandoz’s Denosumab Biosimilars FDA Approved; Terns Pharma’s TERN-701 Receives Orphan Drug Designation; Wegovy® Approved in US for Overweight Cardiovascular Risk; Travere Therapeutics Submits sNDA for FILSPARI IgAN Full Approval

BeiGene Receives FDA Accelerated Approval for BRUKINSA in Relapsed/Refractory Follicular Lymphoma BeiGene, Ltd., has declared that the FDA has provided accelerated approval for BRUKINSA® (zanubrutinib) to be used in treating adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), when used alo...

Find More

giant-cell-arteritis-treatment-therapies
Giant-Cell Arteritis Treatment Beyond Glucocorticoids: Exploring Horizons

Giant-cell arteritis (GCA), alternatively referred to as temporal arteritis, is a form of vasculitis primarily impacting arteries, particularly those in proximity to the temples. If left untreated, it may result in notable complications such as loss of vision. Diagnosis of the disease is often complicated by its pr...

Find More

Over the last months, the world has faced one of the most unexpected challenges in the form of a nov.....

Find More

Immune thrombocytopenic purpura (ITP) is a disorder that results in the immune system killing its pl.....

Find More

Axial Spondyloarthritis (axSpA) is an umbrella term for a form of inflammatory form of arthritis ass.....

Find More

The Union of the European countries, also known as the European Union or the EU, is more or less lik.....

Find More

Metachromatic Leukodystrophy (MLD) is a rare hereditary disease characterized by the accumulation of.....

Find More

Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hyperten.....

Find More